Our Focus
- Jennerex is focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors. Our lead product, Pexa-Vec (JX-594), is a proprietary, oncolytic immunotherapy designed to attack cancer through three diverse mechanisms of action. See how it works.
Watch how it works.
Our Progress
- Jennerex's Phase 2 and 2b drug candidates address liver, colorectal and kidney cancers.
View our pipeline -
Learn more about Pexa-Vec
Latest News & Events
- Jennerex Announces Expansion of Intellectual Property Portfolio
- Jennerex announces preliminary results from TRAVERSE, a Phase 2 study in second-line advanced liver cancer
- Jennerex Webcast at Canaccord Genuity 33rd Annual Growth Conference, August 14-15, 2013, Boston, MA
- Jennerex Completes $21.6 Million Private Placement
- Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
- Jennerex Presents Pexa-Vec Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting